Reduced Sleep Quality and Increasing Fatigue in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Abstract Background Sleep quality and health-related quality of life (HRQoL) remain underassessed in hepatocellular carcinoma (HCC). We prospectively assessed sleep quality and HRQoL in patients with HCC undergoing transarterial chemoembolization (TACE), their association with liver function, and prognostic value for survival. Methods 29 patients with HCC undergoing TACE were included. Sleep quality and HRQoL were assessed at baseline (t1), after the first TACE (t2), and at end of follow-up (tEND) using the Pittsburgh Sleep Quality Index (PSQI) and Chronic Liver Disease Questionnaire (CLDQ). Associations with liver function were evaluated using Spearman correlation; overall survival (OS) was analyzed by Kaplan–Meier and Cox regression. Results Among 26 patients with questionnaire data, median baseline PSQI was 6.5 (IQR 3.5–9.0); 73.1% had impaired sleep quality (PSQI ≥ 5). Patients with children had significantly better sleep quality than those without. Overall HRQoL was stable during TACE (p = 0.601), while fatigue worsened significantly (p = 0.016). CLDQ correlated with liver function (Child–Pugh: rho=-0.668, p < 0.001); PSQI did not. Sleep quality and HRQoL were strongly inversely correlated (rho=-0.806, p < 0.001). Median OS was 15.7 months (95% CI 12.1–42.7), numerically longer in patients with good sleep quality (32.0 vs. 12.1 months; p = 0.064). ALBI score was the only independent predictor of OS (HR 10.52, 95% CI 3.40–32.60, p < 0.001). Conclusions Sleep quality and HRQoL are commonly impaired in HCC patients undergoing TACE and closely correlated, with fatigue the most sensitive domain. Neither independently predicted OS after adjustment for liver function. Routine assessment of both parameters should be considered in this population.
Authors
- Michael Bernhard Pitton (ORCID: https://orcid.org/0000-0002-5572-7763)
- Friedrich Foerster (ORCID: https://orcid.org/0000-0002-3234-8891)
- Arndt Weinmann (ORCID: https://orcid.org/0000-0003-1198-1716)
- Jan Weerts
- Alper Cankaya
- Christian Labenz (ORCID: https://orcid.org/0000-0001-8390-9663)
- Beate Katharina Straub (ORCID: https://orcid.org/0000-0002-4857-1561)
- Jens-Uwe Marquardt
- Carolin Zimpel
- Jens Mittler (ORCID: https://orcid.org/0000-0002-2469-6036)
- Dirk Graafen (ORCID: https://orcid.org/0000-0002-2588-2009)
- Marcus-Alexander Wörns
- Simon Johannes Gairing (ORCID: https://orcid.org/0000-0003-3240-5152)
- Tobias Doyle Bäuerle (ORCID: https://orcid.org/0000-0002-0206-6199)
- Felix Hähn (ORCID: https://orcid.org/0000-0001-5122-9014)
- Peter R. Galle (ORCID: https://orcid.org/0000-0001-8294-0992)
- Akin Kapucu
- Roman Kloeckner (ORCID: https://orcid.org/0000-0001-5492-4792)
- Simon Sachse
- Kateryna Shmanko (ORCID: https://orcid.org/0009-0001-0025-7100)
- Fabian Stoehr (ORCID: https://orcid.org/0000-0002-2797-6252)
- Paula Bark (ORCID: https://orcid.org/0009-0000-8133-4536)
- Lukas Müller (ORCID: https://orcid.org/0000-0002-8626-4044)
- Christian M. Lange
- Tilmann Emrich
Institutions
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University Hospital Schleswig-Holstein (DE)
- Klinikum Dortmund (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-17
- DOI
- https://doi.org/10.21203/rs.3.rs-11430959/v1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- preprint
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Merck KGaA
- Eisai
- Servier
- Ipsen
- Norgine